語系:
繁體中文
English
日文
簡体中文
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Helicobacter pylori[electronic resou...
~
Marshall, Barry.
Helicobacter pylori[electronic resource] /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
杜威分類號:
616.92
書名/作者:
Helicobacter pylori/ edited by Hidekazu Suzuki, Robin Warren, Barry Marshall.
其他作者:
Suzuki, Hidekazu.
出版者:
Tokyo : : Springer Japan :, 2016.
面頁冊數:
x, 267 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:
Springer eBooks
標題:
Helicobacter pylori.
標題:
Helicobacter pylori infections.
標題:
Medicine & Public Health.
標題:
Gastroenterology.
標題:
Pathology.
標題:
Hematology.
ISBN:
9784431557050
ISBN:
9784431557043
內容註:
Part I History -- Chapter 1 Brief History of the Discovery of Helicobacter Pylori -- Part II Pathogenesis -- Chapter 2 Human Migration -- Chapter 3 CagA -- Chapter 4 Helicobacter Pylori VacA Exhibits Pleiotropic Actions in Host Cells -- Chapter 5 Autophagy -- Chapter 6 Ghrelin and Gut Hormone -- Chapter 7 Symptom Generation -- Chapter 8 Gastric Non-Helicobacter Pylori Helicobacter: It's Significance in Human Gastric Diseases -- Part III Diagnosis -- Chapter 9 Urea Breath Test & Rapid Urease Test -- Chapter 10 Endoscopic Findings of H. Pylori Infection -- Chapter 11 Gastric Cancer Risk stratification by H. pylori -- Chapter 12 Prevention of Gastric Cancer by Helicobacter Pylori Eradication: Current Evidence and Future Prospects -- Part IV Treatment -- Chapter 13 Trends in Global Eradication Rates -- Chapter 14 Personalized Therapy in H. Pylori Eradication -- Chapter 15 Quadruple Regimens for Helicobacter Pylori Infection -- Chapter 16 Third-Line Eradication Therapy.
摘要、提要註:
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP) Medical authorities worldwide now recommend a "test and treat" strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program. This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
電子資源:
http://dx.doi.org/10.1007/978-4-431-55705-0
Helicobacter pylori[electronic resource] /
Helicobacter pylori
[electronic resource] /edited by Hidekazu Suzuki, Robin Warren, Barry Marshall. - Tokyo :Springer Japan :2016. - x, 267 p. :ill. (some col.), digital ;24 cm.
Part I History -- Chapter 1 Brief History of the Discovery of Helicobacter Pylori -- Part II Pathogenesis -- Chapter 2 Human Migration -- Chapter 3 CagA -- Chapter 4 Helicobacter Pylori VacA Exhibits Pleiotropic Actions in Host Cells -- Chapter 5 Autophagy -- Chapter 6 Ghrelin and Gut Hormone -- Chapter 7 Symptom Generation -- Chapter 8 Gastric Non-Helicobacter Pylori Helicobacter: It's Significance in Human Gastric Diseases -- Part III Diagnosis -- Chapter 9 Urea Breath Test & Rapid Urease Test -- Chapter 10 Endoscopic Findings of H. Pylori Infection -- Chapter 11 Gastric Cancer Risk stratification by H. pylori -- Chapter 12 Prevention of Gastric Cancer by Helicobacter Pylori Eradication: Current Evidence and Future Prospects -- Part IV Treatment -- Chapter 13 Trends in Global Eradication Rates -- Chapter 14 Personalized Therapy in H. Pylori Eradication -- Chapter 15 Quadruple Regimens for Helicobacter Pylori Infection -- Chapter 16 Third-Line Eradication Therapy.
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP) Medical authorities worldwide now recommend a "test and treat" strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program. This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
ISBN: 9784431557050
Standard No.: 10.1007/978-4-431-55705-0doiSubjects--Topical Terms:
641289
Helicobacter pylori.
LC Class. No.: QR201.H44
Dewey Class. No.: 616.92
Helicobacter pylori[electronic resource] /
LDR
:03245nam a2200313 a 4500
001
447496
003
DE-He213
005
20160930114659.0
006
m d
007
cr nn 008maaau
008
161201s2016 ja s 0 eng d
020
$a
9784431557050
$q
(electronic bk.)
020
$a
9784431557043
$q
(paper)
024
7
$a
10.1007/978-4-431-55705-0
$2
doi
035
$a
978-4-431-55705-0
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
QR201.H44
072
7
$a
MJH
$2
bicssc
072
7
$a
MED031000
$2
bisacsh
082
0 4
$a
616.92
$2
23
090
$a
QR201.H44
$b
H475 2016
245
0 0
$a
Helicobacter pylori
$h
[electronic resource] /
$c
edited by Hidekazu Suzuki, Robin Warren, Barry Marshall.
260
$a
Tokyo :
$b
Springer Japan :
$b
Imprint: Springer,
$c
2016.
300
$a
x, 267 p. :
$b
ill. (some col.), digital ;
$c
24 cm.
505
0
$a
Part I History -- Chapter 1 Brief History of the Discovery of Helicobacter Pylori -- Part II Pathogenesis -- Chapter 2 Human Migration -- Chapter 3 CagA -- Chapter 4 Helicobacter Pylori VacA Exhibits Pleiotropic Actions in Host Cells -- Chapter 5 Autophagy -- Chapter 6 Ghrelin and Gut Hormone -- Chapter 7 Symptom Generation -- Chapter 8 Gastric Non-Helicobacter Pylori Helicobacter: It's Significance in Human Gastric Diseases -- Part III Diagnosis -- Chapter 9 Urea Breath Test & Rapid Urease Test -- Chapter 10 Endoscopic Findings of H. Pylori Infection -- Chapter 11 Gastric Cancer Risk stratification by H. pylori -- Chapter 12 Prevention of Gastric Cancer by Helicobacter Pylori Eradication: Current Evidence and Future Prospects -- Part IV Treatment -- Chapter 13 Trends in Global Eradication Rates -- Chapter 14 Personalized Therapy in H. Pylori Eradication -- Chapter 15 Quadruple Regimens for Helicobacter Pylori Infection -- Chapter 16 Third-Line Eradication Therapy.
520
$a
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP) Medical authorities worldwide now recommend a "test and treat" strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program. This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
650
0
$a
Helicobacter pylori.
$3
641289
650
0
$a
Helicobacter pylori infections.
$3
641290
650
1 4
$a
Medicine & Public Health.
$3
463493
650
2 4
$a
Gastroenterology.
$3
382240
650
2 4
$a
Pathology.
$3
340546
650
2 4
$a
Hematology.
$3
381913
700
1
$a
Suzuki, Hidekazu.
$3
641286
700
1
$a
Warren, Robin.
$3
641287
700
1
$a
Marshall, Barry.
$3
641288
710
2
$a
SpringerLink (Online service)
$3
463450
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-4-431-55705-0
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-4-431-55705-0
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入